SVB Wealth LLC Makes New $231,000 Investment in DexCom, Inc. (NASDAQ:DXCM)

SVB Wealth LLC acquired a new stake in DexCom, Inc. (NASDAQ:DXCM) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 2,975 shares of the medical device company’s stock, valued at approximately $231,000.

Other institutional investors have also modified their holdings of the company. Versant Capital Management Inc acquired a new position in shares of DexCom in the fourth quarter valued at approximately $25,000. Private Trust Co. NA raised its position in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock valued at $26,000 after buying an additional 245 shares during the last quarter. Heck Capital Advisors LLC acquired a new position in shares of DexCom in the fourth quarter valued at approximately $38,000. Midwest Capital Advisors LLC acquired a new position in shares of DexCom in the fourth quarter valued at approximately $54,000. Finally, RPg Family Wealth Advisory LLC acquired a new position in shares of DexCom in the third quarter valued at approximately $57,000. Institutional investors and hedge funds own 97.75% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently weighed in on DXCM shares. Canaccord Genuity Group boosted their price objective on shares of DexCom from $99.00 to $103.00 and gave the company a “buy” rating in a research report on Friday, February 14th. Citigroup boosted their price objective on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research report on Tuesday. Robert W. Baird upgraded shares of DexCom from a “neutral” rating to an “outperform” rating and boosted their target price for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a report on Friday, February 14th. Finally, Redburn Atlantic upgraded shares of DexCom from a “neutral” rating to a “buy” rating and boosted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Four investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $99.82.

DexCom Price Performance

DXCM opened at $81.96 on Thursday. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. DexCom, Inc. has a 52-week low of $62.34 and a 52-week high of $142.00. The company has a 50 day moving average of $84.90 and a two-hundred day moving average of $76.94. The company has a market cap of $32.03 billion, a P/E ratio of 57.31, a P/E/G ratio of 2.30 and a beta of 1.14.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.50 by ($0.05). DexCom had a return on equity of 30.14% and a net margin of 14.29%. On average, analysts expect that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total value of $181,641.90. Following the completion of the transaction, the executive vice president now directly owns 83,526 shares in the company, valued at approximately $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Jacob Steven Leach sold 2,634 shares of the company’s stock in a transaction on Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $228,920.94. Following the completion of the transaction, the chief operating officer now owns 268,644 shares of the company’s stock, valued at $23,347,850.04. This trade represents a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 38,083 shares of company stock worth $3,309,794. 0.30% of the stock is currently owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.